Sermorelin Buy

THE FULL REFERENCE LIST

Sermorelin references: every source pinned to the board

The complete citation set behind this digest, with DOIs, PubMed IDs, and trial registrations. Every quantitative claim on this site resolves to an entry here.

Back to the researchRead the sleep evidence

How to read these references

Every numbered marker across this site resolves to an entry below. Citations are drawn from PubMed-indexed primary studies, editorials, and reviews, plus the FDA's compounding reference. Identifiers (DOI, PMID, NCT, and the former NDA) are included so any claim can be traced to its source. The machine identifiers for the compound itself — CAS 86168-78-7, PubChem CID 16132413, molecular formula C149H246N44O42S, molecular weight 3,357.9 Da — are recorded here as the night-board's pinned fine print.

  1. Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. ↗
  2. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. ↗
  3. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. ↗
  4. Svensson J, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. ↗
  5. Lee H, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003;55(10):1369-1377. ↗
  6. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. ↗
  7. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. NCT00257712. ↗
  8. Behrens S, et al. Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep. Eur J Endocrinol. 2004;151(5):561-566. ↗
  9. Vitiello MV, Moe KE, Merriam GR, et al. Treating age-related changes in somatotrophic hormones, sleep, and cognition. Dialogues Clin Neurosci. 2001;3(3):229-236. ↗
  10. Steiger A, Guldner J, Hemmeter U, et al. Sleep-promoting effects of growth hormone-releasing hormone in normal men. Am J Physiol. 1993;264(4 Pt 1):E594-E598. ↗
  11. Schier T, Guldner J, Colla M, et al. Changes in sleep-endocrine activity after growth hormone-releasing hormone depend on time of administration. J Neuroendocrinol. 1997;9(3):201-205. ↗
  12. Guldner J, Schier T, Friess E, et al. Reduced efficacy of growth hormone-releasing hormone in modulating sleep endocrine activity in the elderly. Neurobiol Aging. 1997;18(5):491-495. ↗
  13. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. ↗
  14. Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. ↗
  15. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov. 2025. ↗